{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T15:06:47Z","timestamp":1775747207864,"version":"3.50.1"},"reference-count":38,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2023,8]]},"DOI":"10.1016\/j.msard.2023.104787","type":"journal-article","created":{"date-parts":[[2023,6,5]],"date-time":"2023-06-05T19:54:16Z","timestamp":1685994856000},"page":"104787","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"special_numbering":"C","title":["Clinical course, imaging, and pathological features of 45 adult and pediatric cases of myelin oligodendrocyte glycoprotein antibody-associated disease"],"prefix":"10.1016","volume":"76","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6799-0801","authenticated-orcid":false,"given":"Hayet","family":"Boudjani","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giulia","family":"Fadda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gabrielle","family":"Dufort","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jack","family":"Antel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul","family":"Giacomini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Myriam","family":"Levesque-Roy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maryam","family":"Oskoui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pierre","family":"Duquette","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexandre","family":"Prat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marc","family":"Girard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rose-Marie","family":"Rebillard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Inge","family":"Meijer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elana","family":"Pinchefsky","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cam-Tu Emilie","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elsa","family":"Rossignol","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jacinthe","family":"Rouleau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Oliver","family":"Blanchard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicole","family":"Khairallah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philippe","family":"Beauchemin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne-Marie","family":"Trudelle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emmanuelle","family":"Lapointe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander","family":"Saveriano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Catherine","family":"Larochelle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.msard.2023.104787_bib0001","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1016\/S1474-4422(21)00218-0","article-title":"Myelin-oligodendrocyte glycoprotein antibody-associated disease","volume":"20","author":"Marignier","year":"2021","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.msard.2023.104787_bib0002","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.jaut.2013.06.008","article-title":"Using EAE to better understand principles of immune function and autoimmune pathology","volume":"45","author":"Rangachari","year":"2013","journal-title":"J. Autoimmun."},{"key":"10.1016\/j.msard.2023.104787_bib0003","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1212\/WNL.0b013e318228c0b1","article-title":"Antibodies to MOG are transient in childhood acute disseminated encephalomyelitis","volume":"77","author":"Probstel","year":"2011","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2023.104787_bib0004","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.1177\/1352458516631038","article-title":"Children with multiphasic disseminated encephalomyelitis and antibodies to the myelin oligodendrocyte glycoprotein (MOG): extending the spectrum of MOG antibody positive diseases","volume":"22","author":"Baumann","year":"2016","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2023.104787_bib0005","doi-asserted-by":"crossref","first-page":"e1858","DOI":"10.1212\/WNL.0000000000005560","article-title":"Clinical spectrum and prognostic value of CNS MOG autoimmunity in adults: the MOGADOR study","volume":"90","author":"Cobo-Calvo","year":"2018","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2023.104787_bib0006","doi-asserted-by":"crossref","first-page":"3128","DOI":"10.1093\/brain\/awx276","article-title":"Clinical presentation and prognosis in MOG-antibody disease: a UK study","volume":"140","author":"Jurynczyk","year":"2017","journal-title":"Brain"},{"key":"10.1016\/j.msard.2023.104787_bib0007","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1212\/WNL.0b013e31826aac4e","article-title":"Myelin-oligodendrocyte glycoprotein antibodies in adults with a neuromyelitis optica phenotype","volume":"79","author":"Kitley","year":"2012","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2023.104787_bib0008","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1177\/13524585221093789","article-title":"Serum MOG-IgG in children meeting multiple sclerosis diagnostic criteria","volume":"28","author":"Fadda","year":"2022","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2023.104787_bib0009","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1002\/ana.25291","article-title":"Pathogenicity of human antibodies against myelin oligodendrocyte glycoprotein","volume":"84","author":"Spadaro","year":"2018","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.msard.2023.104787_bib0010","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/S1474-4422(22)00431-8","article-title":"Diagnosis of myelin oligodendrocyte glycoprotein antibody-associated disease: international MOGAD Panel proposed criteria","volume":"22","author":"Banwell","year":"2023","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.msard.2023.104787_bib0011","doi-asserted-by":"crossref","first-page":"e111","DOI":"10.1212\/WNL.0000000000009758","article-title":"Steroid-sparing maintenance immunotherapy for MOG-IgG associated disorder","volume":"95","author":"Chen","year":"2020","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2023.104787_bib0012","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1136\/jnnp-2020-323158","article-title":"Prevalence and incidence of neuromyelitis optica spectrum disorder, aquaporin-4 antibody-positive NMOSD and MOG antibody-positive disease in Oxfordshire, UK","volume":"91","author":"O'Connell","year":"2020","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.msard.2023.104787_bib0013","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2022.103884","article-title":"Prevalence, incidence, and season distribution of MOG antibody-associated disease in the province of Verona, Italy","volume":"63","author":"Orlandi","year":"2022","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2023.104787_bib0014","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1177\/1352458519845112","article-title":"The clinical spectrum and incidence of anti-MOG-associated acquired demyelinating syndromes in children and adults","volume":"26","author":"de Mol","year":"2020","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2023.104787_bib0015","article-title":"Myelin oligodendrocyte glycoprotein (MOG) antibody positive patients in a multi-ethnic canadian cohort","volume":"11","author":"Cross","year":"2020","journal-title":"Front. Neurol."},{"key":"10.1016\/j.msard.2023.104787_bib0016","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1186\/s12974-016-0718-0","article-title":"MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 2: epidemiology, clinical presentation, radiological and laboratory features, treatment responses, and long-term outcome","volume":"13","author":"Jarius","year":"2016","journal-title":"J. Neuroinflamm."},{"key":"10.1016\/j.msard.2023.104787_bib0017","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2022.104168","article-title":"The prevalence, demographics, clinical features, neuroimaging, and inter-ethnic differences of MOGAD in Malaysia with global perspectives","volume":"67","author":"Ong","year":"2022","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2023.104787_bib0018","doi-asserted-by":"crossref","DOI":"10.1016\/j.jneuroim.2020.577431","article-title":"Seasonal variation of onset in patients with anti-aquaporin-4 antibodies and anti-myelin oligodendrocyte glycoprotein antibody","volume":"349","author":"Akaishi","year":"2020","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.msard.2023.104787_bib0019","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1016\/j.cell.2015.08.025","article-title":"Melatonin contributes to the seasonality of multiple sclerosis relapses","volume":"162","author":"Farez","year":"2015","journal-title":"Cell"},{"key":"10.1016\/j.msard.2023.104787_bib0020","doi-asserted-by":"crossref","DOI":"10.1007\/s13760-022-02103-y","article-title":"Seasonal and monthly variation in multiple sclerosis relapses: a systematic review and meta-analysis","author":"Nabizadeh","year":"2022","journal-title":"Acta Neurol. Belg."},{"key":"10.1016\/j.msard.2023.104787_bib0021","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.28871","article-title":"Comparison of spinal cord magnetic resonance imaging features among children with acquired demyelinating syndromes","volume":"4","author":"Fadda","year":"2021","journal-title":"JAMA Netw. Open"},{"key":"10.1016\/j.msard.2023.104787_bib0022","doi-asserted-by":"crossref","first-page":"e543","DOI":"10.1212\/NXI.0000000000000543","article-title":"Cranial nerve involvement in patients with MOG antibody-associated disease","volume":"6","author":"Cobo-Calvo","year":"2019","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"10.1016\/j.msard.2023.104787_bib0023","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000200020","article-title":"Myelin oligodendrocyte glycoprotein antibody-associated disease presenting as intracranial hypertension: a case report","volume":"9","author":"Chaudhuri","year":"2022","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"10.1016\/j.msard.2023.104787_bib0024","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.msard.2018.10.003","article-title":"Atypical Anti-MOG syndrome with aseptic meningoencephalitis and pseudotumor cerebri-like presentations","volume":"27","author":"Narayan","year":"2019","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2023.104787_bib0025","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2020.102191","article-title":"A case of myelin oligodendrocyte glycoprotein-antibody-associated disease presenting with tumefactive demyelinating lesion","volume":"43","author":"Ataka","year":"2020","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2023.104787_bib0026","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.msard.2018.10.012","article-title":"Aphasic status epilepticus preceding tumefactive left hemisphere lesion in anti-MOG antibody associated disease","volume":"27","author":"Katsuse","year":"2019","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2023.104787_bib0027","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2020.102423","article-title":"Recurrent episodes of syncope requiring pacemaker implantation as an initial presentation of neuromyelitis optica spectrum disorder","volume":"45","author":"Tsouris","year":"2020","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2023.104787_bib0028","doi-asserted-by":"crossref","first-page":"e1097","DOI":"10.1212\/WNL.0000000000012467","article-title":"Comparison of MRI lesion evolution in different central nervous system demyelinating disorders","volume":"97","author":"Sechi","year":"2021","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2023.104787_bib0029","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1001\/jamaneurol.2019.2940","article-title":"Serial anti-myelin oligodendrocyte glycoprotein antibody analyses and outcomes in children with demyelinating syndromes","volume":"77","author":"Waters","year":"2020","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.msard.2023.104787_bib0030","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2022.103664","article-title":"Centrally-located transverse myelitis would facilitate the differentiation of NMOSD and MOG-AD from MS","volume":"60","author":"Etemadifar","year":"2022","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2023.104787_bib0031","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2022.103525","article-title":"OCT retinal nerve fiber layer thickness differentiates acute optic neuritis from MOG antibody-associated disease and Multiple Sclerosis: RNFL thickening in acute optic neuritis from MOGAD vs MS","volume":"58","author":"Chen","year":"2022","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2023.104787_bib0032","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2022.104237","article-title":"Details and outcomes of a large cohort of MOG-IgG associated optic neuritis","volume":"68","author":"Chen","year":"2022","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2023.104787_bib0033","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2020.102456","article-title":"Resolution of myelin oligodendrocyte glycoprotein (MOG)-IgG optic neuritis without treatment","volume":"46","author":"Vosoughi","year":"2020","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2023.104787_bib0034","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1186\/s12974-019-1521-5","article-title":"Optical coherence tomography in myelin-oligodendrocyte-glycoprotein antibody-seropositive patients: a longitudinal study","volume":"16","author":"Oertel","year":"2019","journal-title":"J. Neuroinflamm."},{"key":"10.1016\/j.msard.2023.104787_bib0035","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2020.102251","article-title":"Treatment of MOG-IgG-associated disorder with rituximab: an international study of 121 patients","volume":"44","author":"Whittam","year":"2020","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2023.104787_bib0036","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1007\/s00401-020-02132-y","article-title":"The pathology of central nervous system inflammatory demyelinating disease accompanying myelin oligodendrocyte glycoprotein autoantibody","volume":"139","author":"Hoftberger","year":"2020","journal-title":"Acta Neuropathol."},{"key":"10.1016\/j.msard.2023.104787_bib0037","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1093\/brain\/awaa102","article-title":"Myelin oligodendrocyte glycoprotein antibody-associated disease: an immunopathological study","volume":"143","author":"Takai","year":"2020","journal-title":"Brain"},{"key":"10.1016\/j.msard.2023.104787_bib0038","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2020.102696","article-title":"Interleukin-6 inhibition with tocilizumab for relapsing MOG-IgG associated disorder (MOGAD): a case-series and review","volume":"48","author":"Elsbernd","year":"2021","journal-title":"Mult. Scler. Relat. Disord."}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034823002894?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034823002894?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T09:07:53Z","timestamp":1761901673000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034823002894"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8]]},"references-count":38,"alternative-id":["S2211034823002894"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2023.104787","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2023,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical course, imaging, and pathological features of 45 adult and pediatric cases of myelin oligodendrocyte glycoprotein antibody-associated disease","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2023.104787","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Crown Copyright \u00a9 2023 Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"104787"}}